Lavoltidine

Cat. No.:	HY-121450
CAS No.:	76956-02-0
Molecular Formula:	$C_{19}H_{29}N_5O_2$
Molecular Weight:	359.47
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Lavoltidine (Loxtidine) is an an orally active, irreversible and highly potent histamine H2-receptor antagonist. Lavoltidine strongly inhibits gastric acid secretion and also induces hypergastrinemia[1].
IC_{50} & Target	H_2 Receptor
In Vivo	Lavoltidine (Loxtidine; 0.5 g/L; orally (drinking water); changed weekly; for 3 months) shows partial suppression of both gastric acid secretion and progression to neoplasia. Lavoltidine inhibits gastric atrophy, hyperplasia, and dysplasia in H felis-infected INS-GAS mice[1]. Lavoltidine treatment for 6 months inhibits gastric tumors in H felis-infected INS-GAS mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male hypergastrinemic mice (INS-GAS mice) infected with Helicobacter felis[1]
Dosage:	0.5 g/L
Administration:	Orally (drinking water); changed weekly; for 3 months
Result:	Showed partial suppression of both gastric acid secretion and progression to neoplasia.

REFERENCES

[1]. Takaishi S, et al. Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA